United Therapeutics Corporation filings document an operating biotechnology company with Nasdaq-listed common stock and a public benefit corporation structure. Recent 8-K reports cover quarterly and annual operating results, business updates, clinical-study announcements for Tyvaso and ralinepag, and capital actions such as share repurchase programs and accelerated share repurchase agreements.
Proxy materials describe board elections, director changes, executive compensation, shareholder voting matters and governance practices. The company’s formal disclosures also address its treprostinil-centered pulmonary arterial hypertension business, development programs in pulmonary and transplant-related medicine, and common-stock capital structure.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt reported an exercise-and-sale transaction in company stock. She exercised stock options to acquire 9,500 shares of common stock at an exercise price of $146.03 per share and sold 9,500 shares in multiple open-market trades on May 8, 2026 at weighted average prices generally between the high $560s and low $570s per share. The filing states these transactions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, which is scheduled to continue until the earlier of the exercise of 1,734,410 stock options expiring on March 17, 2027, or December 31, 2026. After these transactions, Rothblatt directly holds 40,513 shares of common stock and has additional indirect holdings through various family trusts and her spouse.
United Therapeutics Corp CFO and Treasurer James Edgemond reported an exercise-and-sell transaction in company stock. On May 7, 2026, he exercised stock options to acquire 10,000 shares of Common Stock at an exercise price of $135.42 per share and sold 10,000 shares of Common Stock in a series of open-market sales at prices around the high-$500 range per share. The filing notes that the option exercise and subsequent sales were carried out under a pre-arranged Rule 10b5-1 trading plan, indicating the trades were scheduled in advance rather than timed discretionarily.
United Therapeutics Chairperson and CEO Martine Rothblatt reported an exercise-and-sell transaction in company stock. On May 7, 2026, she exercised 9,500 stock options at $146.03 per share and sold 9,500 common shares in multiple open‑market trades under a pre‑arranged Rule 10b5‑1 trading plan.
After these transactions, she directly holds 49,513 common shares and also has additional indirect holdings through family trusts and her spouse.
United Therapeutics executive vice president and general counsel Paul A. Mahon exercised stock options and sold the resulting shares in a planned transaction. On May 7, 2026, he exercised options for 8,300 shares of common stock at a strike price of $146.03 per share and carried out open‑market sales totaling 8,300 shares.
The sales were executed in multiple trades at prices including about $597.54, $596.19, $588.51 and several weighted‑average prices in the mid‑$580s, according to footnotes. The filing states these transactions were made under a pre‑arranged Rule 10b5‑1 trading plan, indicating they were scheduled in advance rather than timed discretionarily.
United Therapeutics Corp Chairperson & CEO Martine A. Rothblatt reported an exercise-and-sell transaction in company stock. She exercised stock options to acquire 9,500 shares of common stock at $146.03 per share, then sold 9,500 shares in multiple open-market trades, including 1,513 shares at $595.02 per share, under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025. The filing also lists substantial indirect holdings in family trusts and by her spouse.
Paul Mahon submitted a Form 144 notice to sell 8,300 shares of Common Stock associated with a Stock Option Exercise dated 05/07/2026. The filing lists prior sales of 8,300-share blocks on 04/16/2026, 04/02/2026, 03/19/2026, 03/05/2026, and 02/19/2026.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine A. Rothblatt exercised stock options and sold common shares in a planned sequence. On May 5, 2026, she exercised 9,500 stock options at $146.03 per share and sold 9,500 common shares in multiple open-market trades around the high-$500s.
The filing shows these actions were made under a pre-arranged Rule 10b5-1 trading plan adopted on November 7, 2025, designed to run until the earlier of exercising 1,734,410 options expiring on March 17, 2027 or December 31, 2026. After the transactions, she directly holds 40,513 common shares and also has additional indirect holdings through various family trusts and a spouse account.
United Therapeutics reported softer first quarter 2026 results, with revenue and profit declining versus last year. Total revenues fell 2% to $781.5 million from $794.4 million, while net income declined 15% to $274.9 million. Diluted earnings per share decreased to $5.82 from $6.63.
Tyvaso DPI revenues grew 9% to $330.3 million, but were offset by lower Nebulized Tyvaso and Remodulin sales, resulting in a 2% decline in total Tyvaso revenues to $457.5 million. Cost of sales rose sharply, partly due to a $26.8 million estimated loss on a Tyvaso DPI commercial supply agreement.
The company authorized a share repurchase program of up to $2.0 billion through March 9, 2027 and entered into accelerated share repurchase agreements for approximately $1.5 billion. During the quarter it received 2,164,459 shares, leaving $500 million available under the authorization. Cash, cash equivalents, and marketable investments totaled $3.47 billion as of March 31, 2026.
United Therapeutics reported quarterly net income of $274.9M, down from $322.2M a year earlier, on total revenues of $781.5M versus $794.4M. Higher cost of sales, including Tyvaso DPI inventory reserves and a $26.8M loss tied to a supply agreement, compressed operating income.
The company executed a large capital return, recording a $1.5B accelerated share repurchase in March 2026 under a new $2.0B program, following completion of a prior $1.0B program. Cash and cash equivalents were $1,279.7M and marketable investments $2,191.4M as of March 31, 2026, supporting continued R&D investment.
Phase 3 data were strong for key pipeline assets. Nebulized Tyvaso met primary endpoints in two IPF studies (TETON-1 and TETON-2), with integrated analysis showing a 111.8 mL absolute FVC benefit versus placebo at week 52 (p<0.0001). The ADVANCE OUTCOMES trial of oral ralinepag reduced risk of clinical worsening in PAH by 55% (hazard ratio 0.45, p<0.0001), with significant secondary endpoint improvements, and the company is preparing U.S. regulatory filings.
UNITED THERAPEUTICS Corp Chairperson & CEO Martine Rothblatt exercised stock options to acquire 9,500 shares of common stock at $146.03 per share, then sold 9,500 shares in multiple open‑market trades at prices between roughly $568 and $583. These transactions were made under a pre‑arranged Rule 10b5‑1 trading plan adopted on November 7, 2025.
After the transactions, she held 49,973 shares directly and maintained substantial indirect holdings through family trusts and her spouse, including 324,443, 258,117 and 45,596 shares. The trading plan will continue until either 1,734,410 stock options expiring on March 17, 2027 are exercised or December 31, 2026, whichever occurs first.